绿叶制药(02186.HK)血脂康国际化进程加速向阿斯利康授予血脂康胶囊新加坡独家推广权
格隆汇获悉，2019年8月26日，绿叶制药集团(02186.HK)宣布与阿斯利康签署协议，授权后者在新加坡独家推广天然调脂药血脂康胶囊。今年3月，双方已就该产品的全球商业化达成战略合作备忘录。本次协议的签订，标志着血脂康国际化进程的加速推进。
血脂康胶囊在新加坡的注册商品名为Lipascor®。根据协议，阿斯利康负责Lipascor®在新加坡的独家推广，而绿叶制药继续持有该药品的资产权、销售权、注册准证、全部知识产权等推广权之外的权利。
血脂康胶囊是绿叶制药自主研发的天然调脂药物，已在美国完成FDA II期临床研究，并在新加坡获得新加坡卫生科学局批准上市。此外，该产品还在中国大陆地区、台湾、香港以及马来西亚等市场有售，其调脂疗效和安全性已获得国内外多项大型临床循证医学研究证实，并在长期临床应用中获得各国医生和患者的广泛认可。
为了加速将这一高品质天然药物推向更多国际市场，今年3月，绿叶制药与阿斯利康签署战略合作备忘录，就血脂康胶囊的全球商业化进行深入合作，特别是就进入新兴市场与美国市场的合作加强沟通。双方期望借助各自在海内外市场的资源优势和产品优势，共同携手将血脂康胶囊推广至全球更多国家和地区，助推国内高品质药物的国际化进程。
谈及合作展望，绿叶制药集团管理层充满信心：“阿斯利康在心血管领域丰富的经验、优秀的学术推广能力及广泛的业务网络，能为血脂康胶囊在新加坡当地带来更具广度和深度的覆盖，切实有效地帮助更多有需要的心血管患者。新加坡是我们双方国际化合作的第一站，具有重要的里程碑意义。我们期待与阿斯利康一起，加速拓展血脂康胶囊在各国际市场的发展空间，此举亦是绿叶制药国际化战略的进一步推进。”
另悉，今年1月，阿斯利康已获得血脂康胶囊在中国大陆地区的独家推广权，开创了大型跨国药企推广国内高品质天然药物的先河。双方强强联合，已取得良好的合作开端，血脂康胶囊的在华销售市场和渠道覆盖得以显著拓展。
据悉，血脂康胶囊为绿叶制药集团旗下产品，是利用现代工艺发酵特制红曲制成的纯天然调脂药。血脂康胶囊有调节异常血脂的作用，可降低血胆固醇、甘油三酯、低密度脂蛋白胆固醇和升高高密度脂蛋白胆固醇；抑制动脉粥样硬化斑块的形成，保护血管内皮细胞；抑制脂质在肝脏沉积。该产品已通过国内外多项循证医学临床研究验证，降脂效果已获国际认可。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
